Dr. Agarwal's Health Care Limited has submitted to the Exchange, the financial results for the period ended Jun 30, 2025.
AGARWALEYE · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Dr. Agarwal's Health Care reported strong Q1 FY2026 consolidated results with total income of ₹501 crore, up 22.3% year-on-year from ₹409 crore. Revenue from operations grew 20.8% to ₹487 crore, with India revenue rising 21.4% to ₹440 crore. EBITDA surged 28.9% YoY to ₹141 crore, with margins expanding by 140 basis points to 28.2%. Profit after tax more than doubled, rising 108.9% YoY to ₹38 crore, taking PAT margin to 7.6% from 4.4%. The network expanded to 249 facilities with 13 new centres added during the quarter, including a strategic entry into Delhi. The company performed nearly 79,000 surgeries (up 16% YoY) and served over 7 lakh patients. Auditors Deloitte Haskins & Sells issued an unmodified limited review opinion on the results.
Strong beat on all key metrics with broad-based growth and margin expansion signals healthy operational momentum. The >100% PAT growth and consistent network expansion are positive signals for shareholders, likely to be viewed favourably by the market.